Literature DB >> 7082701

Disruption of selective attention in the rat following chronic d-amphetamine administration: relationship to schizophrenic attention disorder.

A Crider, P R Solomon, M A McMahon.   

Abstract

In the blocking paradigm, prior training to one conditioned stimulus (CSA) blocks the ability to attend to a second conditioned stimulus (CSB) when the two form a compound (CSAB) in subsequent training. Blocking is an associative process by which animals learn to ignore CSB because it contains no new information regarding the reinforcing event. Experiment 1 showed that d-amphetamine disrupted rats' ability to ignore the irrelevant CSB: The animals responded equally to both elements of the CSAB compound following five dialy administrations of 4 mg/kg d-amphetamine. In Experiment 2 the disruption of blocking by d-amphetamine was eliminated by concomitant administration of 0.02 mg/kg haloperidol. These results are consistent with previous research showing that d-amphetamine disrupts rats' ability to ignore repeated presentations of a single nonreinforced stimulus in the latent inhibition paradigm. The inability of amphetamine-treated animals to ignore one element of a dual-element compound bears some resemblance to selective attention deficits seen among schizophrenic patients.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7082701

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  12 in total

1.  Memories reactivated under ketamine are subsequently stronger: A potential pre-clinical behavioral model of psychosis.

Authors:  Michael J Honsberger; Jane R Taylor; Philip R Corlett
Journal:  Schizophr Res       Date:  2015-02-24       Impact factor: 4.939

2.  Blocking of conditioning to a cocaine-paired stimulus: testing the hypothesis that cocaine perpetually produces a signal of larger-than-expected reward.

Authors:  Leigh V Panlilio; Eric B Thorndike; Charles W Schindler
Journal:  Pharmacol Biochem Behav       Date:  2007-03-15       Impact factor: 3.533

3.  Persistent alterations in cognitive function and prefrontal dopamine D2 receptors following extended, but not limited, access to self-administered cocaine.

Authors:  Lisa A Briand; Shelly B Flagel; M Julia Garcia-Fuster; Stanley J Watson; Huda Akil; Martin Sarter; Terry E Robinson
Journal:  Neuropsychopharmacology       Date:  2008-02-27       Impact factor: 7.853

4.  Disruption of the US pre-exposure effect and latent inhibition in two-way active avoidance by systemic amphetamine in C57BL/6 mice.

Authors:  Tilly Chang; Urs Meyer; Joram Feldon; Benjamin K Yee
Journal:  Psychopharmacology (Berl)       Date:  2006-12-19       Impact factor: 4.530

Review 5.  Cognitive enhancers for facilitating drug cue extinction: insights from animal models.

Authors:  Bríd Áine Nic Dhonnchadha; Kathleen M Kantak
Journal:  Pharmacol Biochem Behav       Date:  2011-02-02       Impact factor: 3.533

6.  A rat model of distractibility: effects of drugs modifying dopaminergic, noradrenergic and GABAergic neurotransmission.

Authors:  A Agmo; C Belzung; C Rodríguez
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

7.  Opioid regulation of Pavlovian overshadowing in fear conditioning.

Authors:  Moriel Zelikowsky; Michael S Fanselow
Journal:  Behav Neurosci       Date:  2010-08       Impact factor: 1.912

Review 8.  A neurocognitive animal model dissociating between acute illness and remission periods of schizophrenia.

Authors:  Martin Sarter; Vicente Martinez; Rouba Kozak
Journal:  Psychopharmacology (Berl)       Date:  2008-07-10       Impact factor: 4.530

9.  Kamin blocking is associated with reduced medial-frontal gyrus activation: implications for prediction error abnormality in schizophrenia.

Authors:  Paula M Moran; Jennifer L Rouse; Benjamin Cross; Rhiannon Corcoran; Martin Schürmann
Journal:  PLoS One       Date:  2012-08-31       Impact factor: 3.240

10.  Dopamine D1 receptor involvement in latent inhibition and overshadowing.

Authors:  Andrew J D Nelson; Karen E Thur; Helen J Cassaday
Journal:  Int J Neuropsychopharmacol       Date:  2011-12-16       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.